Charles Rudin, MD
Enriched profileChief, Thoracic Oncology Service; Sylvia Hassenfeld Chair in Lung Cancer Research; Co-Director, Druckenmiller Center for Lung Cancer Research; Deputy Director, MSK Cancer Center · Memorial Sloan Kettering Cancer Center
Charles Rudin is Chief, Thoracic Oncology Service; Sylvia Hassenfeld Chair in Lung Cancer Research; Co-Director, Druckenmiller Center for Lung Cancer Research; Deputy Director, MSK Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 1,711 publications with 88,594 citations (h-index 135); ClinicalTrials.gov lists 15 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory. Clarivate lists Charles Rudin as a Highly Cited Researcher (Clinical Medicine, 2019-2025).
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Charles Rudin, MD, PHD, is Chief, Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center. The public record shows 1,711 publications with 88,594 citations (h-index 135), centered on Lung Cancer Research Studies, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 15 registered clinical trials, industry payments reported by 25 companies, 7 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Research Studies
- 15 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 130 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 452.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 15 registered studies on ClinicalTrials.gov. The most recent:
- DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Sponsor: ECOG-ACRIN Cancer Research Group
Industry payments
Updated 14 Oct 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20257 payments$14,135openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202510 payments$13,051openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
39%Serotonin-3 Receptor Antagonist20.7%Ondansetron Hcl100%Part D<11 patientsCorticosteroid18.3%Prednisone100%Part D<11 patientsSensory organs
20.7%Corticosteroid20.7%Dexamethasone100%Part D≥13 patientsCancer & immunology
16%Kinase inhibitor10.8%Tagrisso100%Part D<11 patientsOther antineoplastic agents5.2%Krazati100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
7 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Coordinating center for the NCI small cell lung cancer research consortium
Sloan-Kettering Inst Can Research
FY2026$1,149,864U24CA213274 - Novel therapeutic development for small cell lung cancer
Sloan-Kettering Inst Can Research
FY2026$1,062,000R35CA263816
Congress activity
Updated 14 Oct 2026
210 congress contributions (2004–2025) across AACR, ASCO, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract 6382: DNA damage repair pathways enable a drug-tolerant persister state in RET-fusion NSCLC and precedes TKI resistance
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- LIF-Induced Tumor Plasticity Establishes an Immunosuppressive Myeloid Niche in LKB1-Mutant Lung Cancer.
Cancer discovery
Article2026 - The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.
Clinical cancer research
Article2026 - L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis.
Nature communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerArticle9,487 citations2015
- 02Tumor mutational load predicts survival after immunotherapy across multiple cancer typesArticle4,399 citations2019
- 03Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsArticle1,754 citations2014
- 04<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung AdenocarcinomaArticle1,624 citations2018
- 05Small-cell lung cancerArticle1,552 citations2021
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/charles-rudin-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
synapse.mskcc.org/synapse/people/13476
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synapse.mskcc.org ↗ - Other
mskcc.org/cancer-care/doctors/charles-rudin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Other
mskcc.org/research-areas/labs/charles-rudin
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - ResearchGate
researchgate.net/scientific-contributions/Charles-M-Rudin-39826127
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/charlesrudin
Mentions by others
where others cite or feature them- Facebook
facebook.com/IASLC/posts/dr-charles-rudin-of-memorial-sloan-kettering-cancer-center-discusses-ongoing-imm/1692604060786666
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
mskcc.org/videos/meet-charles-rudin-thoracic-medical-oncologist-at-msk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Chicago Pritzker School of Medicine (Medical Scientist Training Program)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →the-asci.org ↗ - PhD
University of Chicago Pritzker School of Medicine (Medical Scientist Training Program)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →the-asci.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗
- Member
National Cancer Institute Board of Scientific Advisors
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Principal Investigator
two Stand Up to Cancer grants at MSK
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗ - Member
Scientific Advisory Board, Lung Cancer Research Foundation
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lungcancerresearchfoundation.org ↗
Highly Cited Researcher
Clarivate's annual list, by award category and year- Clinical Medicine2019202020212022202320242025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
- Paul A. Bunn
Jr. Scientific Award (lifetime achievement in thoracic cancer research), International Association for the Study of Lung Cancer
2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iaslc.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →the-asci.org ↗
- Outstanding Investigator Award
National Cancer Institute
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗ - Elected member
Association of American Physicians
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →mskcc.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
- Faculty
Weill Cornell Graduate School of Medical Sciences (Pharmacology)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →gradschool.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →outcomes4me.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center